Disposition of a novel and potent α_vβ₃ antagonist in animals, and extrapolation to man

Reference

• AYRTON, A. and MORGAN, P., 2001, Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica, 31, 469–497.
   PubMed Web of Science ®Google Scholar
• BENET, L. Z. and GALEAZZI, R. L., 1971, Noncompartmental determination of the steady-state volume of distribution. Journal of Pharmaceutical Sciences, 68, 1071–1074.
   Web of Science ®Google Scholar
• BOXENBAUM, H., 1979, Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmacology, 8, 165–176.
   Google Scholar
• BOXENBAUM, H., 1982, Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmacology, 10, 201–227.
   PubMedGoogle Scholar
• COLEMAN, P., ASKEW, B., HUTCHINSON, J., WHITMAN, D., PERKINS, J., HARTMAN, G., RODAN, G., LEU, C., PRUEKSARITANON T., FERNANDEZ-METZLER, C., MERKLE, K., LYNCH, R., LYNCH, J., RODAN, S. and DUGGAN, M., 2002, Non-peptide alpha(v)beta(3) antagonists. Part 4: Potent and orally bioavailable chain-shortened RGD mimetics. Bioorganic and Medical Chemistry Letters, 12, 2463–2466.
   Google Scholar
• CRIPPES, B. A., ENGLEMAN, V. W., SETTLE, S. L., DELARCO, J., ORNBERG, R. L., HELFRICH, M. H., HORTON, M. A. and MuRoLs, G. A., 1998, Antibody to 33 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology, 137, 918–924.
   Web of Science ®Google Scholar
• ENGLEMAN, V. W., NICKOLS, G. A., Ross, F. P., HORTON, M. A., GRIGGS, D. W., SETTLE, S. L., RUMINSKI, P. G. and TEITELBAUM, S. L., 1997, A peptidomimetic antagonist of the V3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. Journal of Clinical Investigation, 99, 2284–2292.
   PubMed Web of Science ®Google Scholar
• HARTMAN, G. D. and DUGGAN, M. E., 2000, Alpha (v) beta (3) integrin antagonists as inhibitors of bone resorption. Expert Opinion on Investigational Drugs, 9, 1281–1291.
   PubMed Web of Science ®Google Scholar
• HUTCHINSON, J. H., HALCZENKO, W., BRASHEAR, K. M., BRESLIN, M. J., COLEMAN, P. J., DUONG, L. T., FISHER, J. E., Fernandez-Metzler, C., GENTILE, M. A., GORHAM, L., HARTMAN, G. H., HUFF, J. H., KIMMEL, D. B., LEU, C.-T., MEISSNER, R. S., Meng, Y., MERKLE, K., NAGY, R., PENNYPACKER, B., PERKINS, J. J., PRUEKSARITANONT, T., RODAN, G. A., Wesolowski, G. A., ZARTMAN, A. E., RODAN, S. B. and DUGGAN, M. E., Nonpeptide 043 antagonists. The in vitro and in vivo evaluation of a potent 003 antagonist for the prevention of osteoporosis. Paper 223 presented at the ACS National Meeting, Boston, MA, August 2002.
   Google Scholar
• KEENAN, R. M., MILLER, W. H., KWON, C., ALI, F. E., CALLAHAN, J. F., CALVO, R. R., HWANG, S.-M., KOPPLE, K. D., PEISHOFF, C. E., SAMANEN, J. M., WONG, A. S., YUAN, C.-K. and HUFFMAN, W. F., 1997, Discovery of potent nonpeptide vitronectin receptor (v3) antagonists. Journal of Medical Chemistry, 40, 2289–2292.
   Google Scholar
• KEENAN, R. M., MILLER, W. H., LAGO, M. A., ALI, F. E., BONDINELL, W. E., CALLAHAN, J. F., CALVO, R. R., COUSINS, R. D., HWANG, S.-M., JAKAS, D. R., Ku, T. W., KWON, C., NGUYEN, T. T., READER, V. A., RIEMAN, D. J., Ross, S. T., TAKATA, D. T., UZINSKAS, I. N., YUAN, C.-K. and SMITH, B. R., 1998, Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (v3) antagonists. Bioorganic and Medical Chemistry Letters, 8, 3165–3170.
   Google Scholar
• LARK, M. W., STROUP, G. B., HWANG, S.-M., JAMES, I. E., RIEMAN, D. J., DRAKE, F. H., BRADBEER, J. N., MATHUR, A., ERHARD, K. F., NEWLANDER, K. A., Ross, S. T., SALYERS, K. L., SMITH, B. R., MILLER, W. H., HUFFMAN, W. F. and GOWEN, M., 1999, Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. Journal of Pharmacology and Experimental Therapeutics, 291, 612–617.
   Google Scholar
• MAHMOOD, I. and BALIAN, J. D., 1996, Interspecies scaling: predicting clearance of drugs in humans: three different approaches. Xenobiotica, 26, 887–895.
   PubMed Web of Science ®Google Scholar
• MILLER, W. H., BONDINELL, W. E., COUSINS, R. D., ERHARD, K. F., JAKAS, D. R., KEENAN, R. M., Ku, T. W., NEWLANDER, K. A., Ross, S. T., HALTIWANGER, R. C., BRADBEER, J., DRAKE, F. H., GOWEN, M., HOFFMAN, S. J., HWANG, S.-M., JAMES, I. E., LARK, M. W., LECHOWSKA, B., RIEMAN, D. J., STROUP, G. B., Vasko-MosER, J. A., ZEMBRYKI, D. L., AZZARANO, L. M., ADAMS, P. C., SALYERS, K. L., SMITH, B. R., WARD, K. W., JOHANSON, K. 0. and HUFFMAN, W. F., 1999, Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorganic and Medical Chemistry Letters, 9, 1807–1812.
   Google Scholar
• MILLER, W. H., KEENAN, R. M., WILLETTE, R. N. and LARK, M. W., 2000, Identification and in vivo efficacy of small-molecule antagonists of integrin 043 (the vitronectin receptor). Drug Discovery Today, 5, 397–408.
   PubMed Web of Science ®Google Scholar
• OIE, S. and TOZER, T. N., 1979, Effect of altered plasma protein on apparent volume of distribution. Journal of Pharmaceutical Sciences, 68, 1203–1205.
   PubMed Web of Science ®Google Scholar
• PRUEKSARITANONT, T., MENG, Y., MA, B., LEPPERT, P., HOCHMAN, J., TANG, C., PERKINS, J., ZRADA, M., MEISSNER, R., DUGGAN, M. E. and LIN, J. H., 2002, Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of avI33 antagonists in rats: limited role of P-glycoprotein. Xenobiotica, 32, 207–220.
   PubMed Web of Science ®Google Scholar
• RODAN, S. B., DUONG, L. T., DUGGAN, M. E., FISHER, J. E., GENTILE, M. A., FERNANDEZ-METZLER, C., HALCZENKO, W., HARTMAN, G., HUTCHINSON, J. H., LEU, C.-T., LIPFERT, L., NAGY, R. M., PENNYPACKER, B., PRUEKSARITANONT, T., SEEDOR, J. G., WESOLOWSKI, G., KIMMEL, D. B. and
   Google Scholar
• RODAN, G. A., 2002, A potent antagonist of ce,133 integrin is a powerful inhibitor of bone resorption in vivo. Bone and Mineral Research, 17, S198.
   Google Scholar
• SAWADA, Y., HANANO, M., SUGIYAMA, Y. and IGA, T., 1984, Prediction of the disposition of 13-lactam antibiotics in humans from pharmacokinetic parameters in animals. Journal of Pharmacokinetics and Biopharmacology, 12, 241–260.
   PubMedGoogle Scholar
• WILKINSON, G. R. and SHANE, D. G., 1975, A physiological approach to hepatic drug clearance. Clinical and Pharmacology Therapy, 18, 377–390.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO, M., FISHER, J. E., GENTILE, M., SEEDOR, J. G., LEU, C.-T., RODAN, S. B. and RODAN, G. A., 1998, The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology, 139, 1411–1419.
   Google Scholar
• YANO, I., Pro, T., TAKANO, M. and INui, K., 1997, Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. Pharmacology Research, 14, 508–511.
   PubMed Web of Science ®Google Scholar